Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J, Regeneron follow Pfizer in clinical holds for anti-NGFs

This article was originally published in Scrip

Executive Summary

The US FDA last week placed clinical holds on the testing of two separate investigational anti-nerve growth factor (NGF) pain drugs under development by Johnson & Johnson and Regeneron Pharmaceuticals and its partner Sanofi-Aventis after a case of avascular necrosis of a joint was confirmed in a clinical trial participant.

You may also be interested in...



Surprise! Pfizer And Lilly File Tanezumab For Pain With FDA Despite Safety Questions

The partners have filed the first-in-class NGF inhibitor at the lower 2.5mg dose for the treatment of osteoarthritis pain, despite the drug’s challenging safety profile.

Pfizer, Lilly Weigh In On Dosing And Safety Of Non-Opioid Pain Drug Tanezumab

Two dosing regimens hit the mark on three co-primary endpoints and the rate of rapidly progressive osteoarthritis was low at 1.3% in a Phase III study of the NGF inhibitor presented on Oct. 23.

Regeneron Revives NGF Inhibitor With Phase II/III Data; Safety Issue Remains

Regeneron Pharmaceuticals Inc. reported statistically significant pain relief for osteoarthritis sufferers enrolled in the company's Phase II/III clinical trial for fasinumab, but the data didn't relieve concerns about neuro-musculoskeletal side effects for medicines that inhibit nerve growth factor (NGF).

Topics

Related Companies

UsernamePublicRestriction

Register

SC011255

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel